Use of the Oncotype DX™ 21-gene assay to guide adjuvant decision making in early-stage breast cancer
Use of the Oncotype DX™ 21-gene assay to guide adjuvant decision making in early-stage breast cancer
复制标题
DOI：
10.1007/bf03256259
复制
发表时间：
2007-01-01
影响因子：
4
通讯作者：
Seidman, Andrew D.
中科院分区：
文献类型：
--
作者：
Conlin, Alison K.;Seidman, Andrew D.
在早期乳腺癌患者中使用辅助化疗的决定涉及考虑许多因素，这些因素传统上严重依赖于肿瘤大小和淋巴结受累以及一组有限的生物学特征，如雌激素受体和HER2表达。细胞毒性化疗的过度治疗是患者和医生的一个重要问题。使用目前公认的指南，据估计，接受化疗的低风险乳腺癌患者中有很大一部分可能是过度治疗。基因表达谱分析是一项正在开发的新技术，用于帮助改善患者的风险分层和预测结果。Oncotype DX（TM）检测是在淋巴结阴性、表达雌激素受体的乳腺癌妇女中验证的基因表达谱的一个例子。该检测和其他检测旨在帮助改善风险分类和复发预测，从而优化辅助化疗患者的选择。
The decision to use adjuvant chemotherapy in patients with early stage breast cancer involves the consideration of many factors that traditionally rely heavily on tumor size and lymph node involvement and a limited set of biologic characteristics such as estrogen receptor and HER2 expression. Overtreatment with cytotoxic chemotherapy is a significant concern among patients and physicians. Using the currently accepted guidelines it has been estimated that a large percentage of patients receiving chemotherapy for low-risk breast cancers may be overtreated. Gene expression profiling is a new technology being developed to help improve risk stratification of patients and to predict outcomes. The Oncotype DX(TM) assay is one example of a gene expression profile validated in women with lymph node-negative, estrogen receptor-expressing breast cancer. This assay and others aim to help improve risk classification and recurrence prediction and, therefore, optimize selection of patients for adjuvant chemotherapy.